380 related articles for article (PubMed ID: 36185603)
1. Safety and efficacy of peptide receptor radionuclide therapy with
Jiang Y; Liu Q; Wang G; Sui H; Wang R; Wang J; Zhang J; Zhu Z; Chen X
Theranostics; 2022; 12(15):6437-6445. PubMed ID: 36185603
[No Abstract] [Full Text] [Related]
2. Dose escalation of an Evans blue-modified radiolabeled somatostatin analog
Liu Q; Cheng Y; Zang J; Sui H; Wang H; Jacobson O; Zhu Z; Chen X
Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):947-957. PubMed ID: 31832728
[TBL] [Abstract][Full Text] [Related]
3. Peptide Receptor Radionuclide Therapy of Late-Stage Neuroendocrine Tumor Patients with Multiple Cycles of
Liu Q; Zang J; Sui H; Ren J; Guo H; Wang H; Wang R; Jacobson O; Zhang J; Cheng Y; Zhu Z; Chen X
J Nucl Med; 2021 Mar; 62(3):386-392. PubMed ID: 32826319
[TBL] [Abstract][Full Text] [Related]
4. Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog
Zhang J; Wang H; Jacobson O; Cheng Y; Niu G; Li F; Bai C; Zhu Z; Chen X
J Nucl Med; 2018 Nov; 59(11):1699-1705. PubMed ID: 29653971
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Safety, Biodistribution, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog 177 Lu-DOTA-EB-TATE With and Without Amino Acid Infusion.
Jiang Y; Liu Q; Wang G; Zhang J; Zhu Z; Chen X
Clin Nucl Med; 2023 Jun; 48(6):e289-e293. PubMed ID: 37075254
[TBL] [Abstract][Full Text] [Related]
6. Peptide receptor radionuclide therapy (PRRT) in metastatic neuroendocrine tumors of unknown primary (CUP-NETs).
Baum RP; Wang P; Jakobsson V; Zhao T; Schuchardt C; Khong PL; Zhang J
Theranostics; 2024; 14(1):133-142. PubMed ID: 38164147
[No Abstract] [Full Text] [Related]
7. First-in-Humans Study of the SSTR Antagonist
Baum RP; Zhang J; Schuchardt C; Müller D; Mäcke H
J Nucl Med; 2021 Nov; 62(11):1571-1581. PubMed ID: 33674401
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcome of indigenous
Sitani K; Parghane RV; Talole S; Basu S
Br J Radiol; 2021 Jan; 94(1117):20201041. PubMed ID: 33095671
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcome of "Sandwich" chemo-PRRT: a novel treatment strategy for metastatic neuroendocrine tumors with both FDG- and SSTR-avid aggressive disease.
Parghane RV; Ostwal V; Ramaswamy A; Bhandare M; Chaudhari V; Talole S; Shrikhande SV; Basu S
Eur J Nucl Med Mol Imaging; 2021 Mar; 48(3):913-923. PubMed ID: 32876706
[TBL] [Abstract][Full Text] [Related]
10. Salvage PRRT with
Rudisile S; Gosewisch A; Wenter V; Unterrainer M; Böning G; Gildehaus FJ; Fendler WP; Auernhammer CJ; Spitzweg C; Bartenstein P; Todica A; Ilhan H
BMC Cancer; 2019 Aug; 19(1):788. PubMed ID: 31395036
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of
Zidan L; Iravani A; Oleinikov K; Ben-Haim S; Gross DJ; Meirovitz A; Maimon O; Akhurst T; Michael M; Hicks RJ; Grozinsky-Glasberg S; Kong G
J Nucl Med; 2022 Feb; 63(2):218-225. PubMed ID: 34049983
[TBL] [Abstract][Full Text] [Related]
12. Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors.
Nicolini S; Bodei L; Bongiovanni A; Sansovini M; Grassi I; Ibrahim T; Monti M; Caroli P; Sarnelli A; Diano D; Di Iorio V; Grana CM; Cittanti C; Pieri F; Severi S; Paganelli G
Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3260-3267. PubMed ID: 33604690
[TBL] [Abstract][Full Text] [Related]
13. Clinical utility of
Parghane RV; Naik C; Talole S; Desmukh A; Chaukar D; Banerjee S; Basu S
Head Neck; 2020 Mar; 42(3):401-416. PubMed ID: 31755622
[TBL] [Abstract][Full Text] [Related]
14. The efficacy, toxicity and survival of salvage retreatment PRRT with
Sitani K; Parghane R; Talole S; Basu S
Br J Radiol; 2022 Sep; 95(1137):20210896. PubMed ID: 35816545
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Lu-177 DOTATATE Peptide Receptor Radionuclide Therapy in Patients with Unresectable or Metastatic Neuroendocrine Tumors in Korea.
Shin Y; Moon BH; Ryoo BY; Chang HM; Kim KP; Hong YS; Kim TW; Ryu JS; Kim YI; Yoo C
Target Oncol; 2024 Jan; 19(1):41-49. PubMed ID: 38108953
[TBL] [Abstract][Full Text] [Related]
16. Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients.
Zhang J; Kulkarni HR; Singh A; Niepsch K; Müller D; Baum RP
J Nucl Med; 2019 Mar; 60(3):377-385. PubMed ID: 30115686
[TBL] [Abstract][Full Text] [Related]
17. 177Lu-DOTATATE PRRT in Patients with Metastatic Neuroendocrine Tumor and a Single Functioning Kidney: Tolerability and Effect on Renal Function.
Ranade R; Basu S
J Nucl Med Technol; 2016 Jun; 44(2):65-9. PubMed ID: 26848166
[TBL] [Abstract][Full Text] [Related]
18. Clinical Response Profile of Metastatic/Advanced Pulmonary Neuroendocrine Tumors to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE.
Parghane RV; Talole S; Prabhash K; Basu S
Clin Nucl Med; 2017 Jun; 42(6):428-435. PubMed ID: 28319500
[TBL] [Abstract][Full Text] [Related]
19. Treatment with tandem [90Y]DOTA-TATE and [177Lu]DOTA-TATE of neuroendocrine tumours refractory to conventional therapy.
Seregni E; Maccauro M; Chiesa C; Mariani L; Pascali C; Mazzaferro V; De Braud F; Buzzoni R; Milione M; Lorenzoni A; Bogni A; Coliva A; Lo Vullo S; Bombardieri E
Eur J Nucl Med Mol Imaging; 2014 Feb; 41(2):223-30. PubMed ID: 24233003
[TBL] [Abstract][Full Text] [Related]
20. Estimation of Absorbed Doses of Indigenously Produced "Direct-route" Lutetium-177-[
Kamaldeep ; Loharkar S; Das T; Basu S; Banerjee S
Cancer Biother Radiopharm; 2022 Apr; 37(3):214-225. PubMed ID: 34910891
[No Abstract] [Full Text] [Related]
[Next] [New Search]
